On July 17, a reporter from People’s Daily Health Channel learned from Guangdong Academy of Sciences that Professor Wu Wenming, deputy director of the National Medical and Health Device Engineering Technology Research Center and scholar of the Hundred Talents Program of the Chinese Academy of Sciences

The director of Columbia University’s Center for Infection and Immunity talked about problems with antigen tests and the need for continued investment in COVID-19 testing.

Two SARS-CoV-2 antigen tests from Watmind USA and Genabio Diagnostics have received Emergency Use Authorization from the US Food and Drug Administration for at-home use without a prescription.

Color Health said on Friday that it has partnered with the US Centers for Disease Control and Prevention to increase access to no-cost, PCR-based, COVID-19 testing.

Quest Diagnostics said Thursday that it is participating in the Centers for Disease Control and Prevention's (CDC) Increasing Community Access to Testing (ICATT) for COVID-19 program.

Recently, Wuhan YZY Biopharma Co., Ltd completed a 200 million CNY Pre-C round of financing. This round of financing was completed by the joint investment of Wuhan Hi-Tech, Hubei Science Technology Investment and Optics Valley Financial Holding Group.

The FDA cautioned in late 2021 after the omicron variant emerged that antigen tests may have reduced sensitivity, meaning they correctly identify fewer people with COVID-19. Data have continued to accumulate that the tests are not as sensitive to the newer variants of the virus, Stenzel said.

Although Covid-19 is not over yet, the market conditions of nucleic acid and antigen detection reagents are rapidly cooling down, and even "cliff-like" subsidence.

Despite significant and stunning advances in vaccine technology, the COVID-19 global pandemic is not over. A key challenge in limiting the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is identifying infected individuals.

FDA issued a recommendation on June 30, 2022 to COVID-19 vaccine manufacturers that indicated that they should include an Omicron subvariant BA.4/5 component in their vaccines.